pocketful logo light
pocketful logo light
Dr Lal Pathlabs Ltd logo

Dr Lal Pathlabs Ltd

NSE: LALPATHLAB BSE: 539524

1568.70

(0.45%)

Fri, 19 Jun 2026, 01:05 pm

Dr Lal Pathlabs Share Price Live Chart

1 Day

(0.45%)

No Result Found

Summary

  • Market Cap (in Cr)

    26817.85

  • Net Profit (in Cr)

    492.25

  • P/B

    9.53

  • Sector P/E

    58.57

  • P/E

    42.52

  • EV/EBITDA

    25.39

  • Debt/Equity (Industry)

    0.18

  • Interest Cover (Industry)

    12.19

  • ROCE (Industry)

    17.69

  • RONW (Industry)

    14.86

  • ROE

    24.48

  • ROCE

    29.22

  • Debt/Equity

    0.10

  • EPS (TTM)

    31.48

  • Dividend Yield

    1.53

  • Book Value

    149.62

  • Interest Cover

    29.01

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters53.2153.2253.2253.7953.91
FII17.1820.2921.8621.6823.91
DII21.3819.2118.4917.9116.08
Public8.227.286.446.626.10
Government0.010.01000

Read More

Technical Analysis

RSI

58.22

MACD

23.45

50 DMA

1543.17

200 DMA

1500.78

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic2232.231902.331754.871572.431424.971242.53912.63
Fibonacci1902.331776.311698.461572.431446.411368.561242.53
Camarilla1698.121667.881637.641572.431577.161546.921516.68

Pivots Level: Classic

R3

+659.80

2232.23

R2

+329.90

1902.33

R1

+182.43

1754.87

1572.43
1572.43
Pivot Point
LTP: 1635.80

S1

-147.47

1424.97

S2

-329.90

1242.53

S3

-659.80

912.63

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1620.86

  • 20-EMA

    1603.73

  • 30-EMA

    1586.01

  • 50-EMA

    1552.29

  • 100-EMA

    1510.18

  • 200-EMA

    1489.98

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
30 Apr 2026board-meetingsAccounts, Quarterly Results
30 Apr 2026dividend₹4.00 Dividend /Share26 Jun 2026
30 Apr 2026agm
30 Jan 2026board-meetingsQuarterly Results
30 Jan 2026dividend₹3.50 Dividend /Share05 Feb 2026
05 Jan 2026dividendInterim Dividend - Rs. - 3.505 Feb 2026
12 Dec 2025bonus1:1 Bonus Issue of Equity Shares12 Dec 2025
19 Nov 2025bonusBonus issue 1:119 Dec 2025
31 Oct 2025dividend₹7.00 Dividend /Share07 Nov 2025
31 Oct 2025board-meetingsQuarterly Results, Half Yearly Results, Interim Dividend, Bonus Issue

Read More

Peer Comparison

Dr Lal Pathlabs Ltd logo

Dr Lal Pathlabs Ltd

Apollo Hospitals Enterprise Ltd logo

Apollo Hospitals Enterprise Ltd

Fortis Healthcare Ltd logo

Fortis Healthcare Ltd

Aster DM Healthcare Ltd logo

Aster DM Healthcare Ltd

Max Healthcare Institute Ltd logo

Max Healthcare Institute Ltd

Narayana Hrudayalaya Ltd logo

Narayana Hrudayalaya Ltd

Read More

Dr Lal Pathlabs Ltd About

Dr. Lal PathLabs is engaged in the business of running laboratories for carrying out pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations.

Industry

Healthcare

Founded

1995

Headquarters

CEO

Arvind Lal

Employees

Contact

Website icon

Website

http://www.lalpathlabs.com

Email icon

Email

cs@lalpathlabs.com

Phone icon

Phone

91-011-3024 4149

Location icon

Location

E-2 Block Sector 18, Rohini, New Delhi, New Delhi, 110085

Read More

Dr Lal Pathlabs Ltd Company History

YearHistory
2017
  • Dr Lal PathLabs is Amalgameted with Ria and Pathology Private Limited
2018
  • Amalgamation of Shree Computerised Pathology Laboratory, Modern Diagnostics & Modern Lab
2021
  • Dr Lal PathLabs Launches Bangalore Reference Laboratory.
2023
  • NCLT has given approval for Amalgamation between Dr. Lal PathLabs Limited and APL Institute of Clinical Laboratory & Research Private Limited.
2024
  • NCLT, Allahabad Bench sanctioned the Scheme of Amalgamation between two Subsidiary Companies of Dr. Lal PathLabs Limited.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GOLDMAN SACHS BANK EUROPE SE - ODIblockBuy33414316020 Oct 2025
GOLDMAN SACHS (SINGAPORE) PTE - ODIblockSell33414316020 Oct 2025
MULTI-MANAGER ICVCbulkSell4349432997.1106 Jan 2025
ISHARES MSCI INDIA SMALL-CAP ETFblockBuy129492550.925 Oct 2022
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy693192550.925 Oct 2022
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell693192550.925 Oct 2022
ISHARES INDIA SC MAURITIUS COMPANYblockSell129492550.925 Oct 2022
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell692502377.517 Oct 2022
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy692502377.517 Oct 2022
ISHARES MSCI INDIA SMALL-CAP ETFblockBuy129342377.517 Oct 2022

Read More

Dr Lal Pathlabs Ltd News

Dr Lal Pathlabs sets up Dubai subsidiary

Dr Lal Pathlabs Ltd incorporated DR LAL PATHLABS FZCO in Dubai on June 12, 2026. The wholly owned subsidiary will invest in diagnostics and allied activities.

12 Jun 2026

companies

Dr. Lal Path Labs: ₹20.56 Cr Block Trade on NSE

A block trade of ~1,26,673 shares of Dr. Lal Path Labs was executed on the NSE, valued at ₹20.56 crores at a price of ₹1622.90 per share.

26 May 2026

equity-markets

Dr. Lal PathLabs to Meet Investors on May 20, 2026

Dr. Lal PathLabs schedules a virtual group/one-on-one meeting with analysts and institutional investors at the Centrum Investor Conference on May 20, 2026.

13 May 2026

companies

Dr. Lal PathLabs FY26 Audited Results: Revenue Up 12.2%

Dr. Lal PathLabs posts FY26 consolidated revenue of INR 27,629 million, up 12.2% YoY. PAT at INR 5,098 million; board recommends final dividend of INR 4/share; Dubai subsidiary incorporation approved.

08 May 2026

investment-ideas

Dr. Lal PathLabs FY26 Results: Revenue Up 12.2%; FY27 Guidance Outlined

Dr. Lal PathLabs reported FY26 revenue of Rs. 2,763 crore, up 12.2%, with a PAT of Rs. 510 crore. Management guides FY27 revenue growth at early to mid-teens and EBITDA margins of 27-28%.

06 May 2026

investment-ideas

Read More

Open Your Free Demat Account

Enter your phone number